MBIO Stock — Mustang Bio Inc.: Cash, EV, Pipeline

Share price

$0.54

Market cap

$4.1M

Cash

$15.2M

Enterprise value

-$11.1M

Balance sheet

Cash	$15.2M
Debt	$0.0M
Net cash	$15.2M
Enterprise value	-$11.1M
Basic shares	6.7M shares
Fully diluted shares	9.2M shares
Fully diluted market cap	$5.0M
Cash per share	$2.26

Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.

Price history

Loading MBIO daily closes…

Loading price history…

Pipeline assets

MB-101

Phase 1 · Active Modality: IL13R-alpha-2-targeted CAR T cell therapy

Target IL13R-alpha-2

Partnerships City of Hope (development partner; investigator-sponsored trials)

Indications

glioblastoma (Phase 1)
malignant brain tumors (Phase 1)

Status note COH Phase 1 treatment phase completed; multiple investigator-sponsored studies enrolling; FDA Orphan Drug Designation July 2025.

MB-108

Phase 1 · Active Modality: HSV-1 oncolytic virus

Partnerships Nationwide (partner)

Indications

malignant glioma (Phase 1)
malignant brain tumors (Phase 1)

Status note UAB Phase 1 ongoing; FDA Orphan Drug Designation November 2024.

MB-109

Preclinical · Active Modality: combination of MB-101 CAR T and MB-108 oncolytic virus

Target IL13R-alpha-2

Partnerships City of Hope; Nationwide

Indications

IL13R-alpha-2-positive recurrent glioblastoma (Preclinical)
high-grade astrocytoma (Preclinical)

Catalysts

— Q4 2026

Status note FDA safe-to-proceed letter October 2023 for Phase 1 IND; investigator-sponsored trial under COH IND potentially initiating Q4 2026.

CD20 CAR-T

Stage not disclosed · Terminated Modality: CAR T cell therapy

Target CD20

Partnerships Fred Hutch (CD20 License terminated December 2025)

Indications

not disclosed (Stage not disclosed)

Status note CD20 License with Fred Hutch terminated December 2025; Mustang eligible for royalties on subsequent Fred Hutch licensing consideration for three years.

Per-asset detail extracted from the 10-Q filed 2026-08-05. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

No lead program on file for this company.

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT02159495	Phase 1	Active, not recruiting	Collaborator	City of Hope Medical Center	—	Adult Acute Myeloid Leukemia in Remission; Acute Biphenotypic Leukemia; Early Relapse of Acute Myeloid Leukemia	—

Sponsor-matched active trials from ClinicalTrials.gov (0 as sponsor, 1 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 1 active trials for City of Hope Medical Center on ClinicalTrials.gov

No specialist-fund holders in 13F data for this company.

MBIO — Mustang Bio Inc.

Balance sheet

Price history

Pipeline assets

Active clinical trials